Search

Limited data are available for ceftazidime–avibactam (CZA) dosing in patients receiving renal replacement therapy, especially the data on the dosing in patients receiving intermittent hemodialysis (IHD). In this report, we firstly described a case in which CZA was administered as 2.5 g after each time of IHD, and a dose of 1.25 g was added on the 48th-hour for the 72-h interdialytic interval. Plasma concentrations of CZA measured at different time indicated that > 50% of administered ceftazidime and avibactam were removed during the 4-h hemodialysis. In addition, we described another case on continuous venovenous hemodialysis (CVVHD), in which CZA was administered as 2.5 g q12h in 2-h infusions. The dose regimen for these two cases could achieve trough concentration of ceftazidime higher than fourfold of the MIC and trough concentration of avibactam higher than the threshold of 1 μg/mL during the treatment, and exert efficient antimicrobial effect. [ABSTRACT FROM AUTHOR]

Correction to: Efficacy and Pharmacodynamic Target Attainment for Ceftazidime-Avibactam Off-Label Dose Regimens in Patients with Continuous or Intermittent Venovenous Hemodialysis: Two Case Reports The original article can be found online at https://doi.org/10.1007/s40121-022-00621-z. Correction to: Infect Dis Ther https://doi.org/10.1007/s40121-022-00621-z In the original publication of the article, there should be three corresponding authors; Chun-Hong Zhang, Xu-Ben Yu and Cong-Rong Tang This has been corrected in this paper. [Extracted from the article]